Antiatherogenic properties of high-density lipoproteins from arterial plasma are attenuated as compared to their counterparts of venous origin.


Journal

Nutrition, metabolism, and cardiovascular diseases : NMCD
ISSN: 1590-3729
Titre abrégé: Nutr Metab Cardiovasc Dis
Pays: Netherlands
ID NLM: 9111474

Informations de publication

Date de publication:
03 01 2020
Historique:
received: 03 05 2019
revised: 15 07 2019
accepted: 28 07 2019
pubmed: 23 11 2019
medline: 1 7 2020
entrez: 23 11 2019
Statut: ppublish

Résumé

High-density lipoprotein (HDL) particles play atheroprotective roles by their ability to efflux cholesterol from foam cells and to protect low-density lipoproteins (LDLs) from oxidative damage in the arterial intima. We hypothesized that antioxidative properties of HDLs can be attenuated in the oxygen-rich prooxidative arterial environment, contributing to the development of atherosclerosis. To evaluate this hypothesis, we compared antioxidative activity of HDLs from arterial and venous plasmas. Arterial and venous blood samples were simultaneously obtained from 16 patients (age 68 ± 10 years; 75% males) presenting with ischemic or valvular heart disease. Major HDL subfractions and total HDLs were isolated by density gradient ultracentrifugation and their chemical composition and the capacity to protect LDLs from in vitro oxidation were evaluated. HDL-cholesterol, triglycerides and apolipoprotein (apo) B-100 levels were slightly but significantly reduced by -4 to -8% (p < 0.01) in the arterial vs. venous samples. Total mass of HDL subpopulations was similar and HDL subpopulations did not reveal marked compositional differences between the arterial and venous circulation. Potent antioxidative activity of the small, dense HDL3c subpopulation was significantly reduced in the particles of arterial origin vs. their counterparts from venous plasma (increase of +21% in the propagation rate of LDL oxidation, p < 0.05). Interestingly, antioxidative properties of venous HDLs were enhanced in statin-treated patients relative to untreated subjects. Antioxidative properties of small, dense HDLs from arterial plasma are attenuated as compared to the particles of venous origin, consistent with the development of atherosclerosis in the arterial wall.

Sections du résumé

BACKGROUND AND AIMS
High-density lipoprotein (HDL) particles play atheroprotective roles by their ability to efflux cholesterol from foam cells and to protect low-density lipoproteins (LDLs) from oxidative damage in the arterial intima. We hypothesized that antioxidative properties of HDLs can be attenuated in the oxygen-rich prooxidative arterial environment, contributing to the development of atherosclerosis. To evaluate this hypothesis, we compared antioxidative activity of HDLs from arterial and venous plasmas.
METHODS AND RESULTS
Arterial and venous blood samples were simultaneously obtained from 16 patients (age 68 ± 10 years; 75% males) presenting with ischemic or valvular heart disease. Major HDL subfractions and total HDLs were isolated by density gradient ultracentrifugation and their chemical composition and the capacity to protect LDLs from in vitro oxidation were evaluated. HDL-cholesterol, triglycerides and apolipoprotein (apo) B-100 levels were slightly but significantly reduced by -4 to -8% (p < 0.01) in the arterial vs. venous samples. Total mass of HDL subpopulations was similar and HDL subpopulations did not reveal marked compositional differences between the arterial and venous circulation. Potent antioxidative activity of the small, dense HDL3c subpopulation was significantly reduced in the particles of arterial origin vs. their counterparts from venous plasma (increase of +21% in the propagation rate of LDL oxidation, p < 0.05). Interestingly, antioxidative properties of venous HDLs were enhanced in statin-treated patients relative to untreated subjects.
CONCLUSION
Antioxidative properties of small, dense HDLs from arterial plasma are attenuated as compared to the particles of venous origin, consistent with the development of atherosclerosis in the arterial wall.

Identifiants

pubmed: 31753791
pii: S0939-4753(19)30290-X
doi: 10.1016/j.numecd.2019.07.022
pii:
doi:

Substances chimiques

Antioxidants 0
Biomarkers 0
Hydroxymethylglutaryl-CoA Reductase Inhibitors 0
Lipoproteins, HDL 0

Types de publication

Comparative Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

33-39

Informations de copyright

Copyright © 2019 The Italian Society of Diabetology, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition, and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.

Auteurs

Dominique Bonnefont-Rousselot (D)

Department of Metabolic Biochemistry, Pitié-Salpêtrière-Charles Foix Hospital, AP-HP, Paris, France; INSERM U 1022 CNRS UMR 8258, Chimie ParisTech, PSL Research University, Laboratory of Chemical and Biological Technologies for Health (UTCBS), Faculty of Pharmacy of Paris, University of Paris, France. Electronic address: dominique.rousselot@aphp.fr.

Leila Benouda (L)

National Institute for Health and Medical Research (INSERM), UMR ICAN 1166, Sorbonne University Paris 6, Pitié-Salpêtrière - Charles Foix Hospital, AP-HP, Paris, France. Electronic address: benouda.l@wanadoo.fr.

Randa Bittar (R)

Department of Metabolic Biochemistry, Pitié-Salpêtrière-Charles Foix Hospital, AP-HP, Paris, France; National Institute for Health and Medical Research (INSERM), UMR ICAN 1166, Sorbonne University Paris 6, Pitié-Salpêtrière - Charles Foix Hospital, AP-HP, Paris, France. Electronic address: randa.bittar@aphp.fr.

Maryam Darabi-Amin (M)

National Institute for Health and Medical Research (INSERM), UMR ICAN 1166, Sorbonne University Paris 6, Pitié-Salpêtrière - Charles Foix Hospital, AP-HP, Paris, France. Electronic address: mdarabi@outlook.com.

Pierre Demondion (P)

Department of Cardiac Surgery, Pitié-Salpêtrière - Charles Foix Hospital, AP-HP, Paris, France. Electronic address: pierre.demondion@aphp.fr.

Philippe Lesnik (P)

National Institute for Health and Medical Research (INSERM), UMR ICAN 1166, Sorbonne University Paris 6, Pitié-Salpêtrière - Charles Foix Hospital, AP-HP, Paris, France. Electronic address: philippe.lesnik@sorbonne-universite.fr.

Pascal Leprince (P)

National Institute for Health and Medical Research (INSERM), UMR ICAN 1166, Sorbonne University Paris 6, Pitié-Salpêtrière - Charles Foix Hospital, AP-HP, Paris, France; Department of Cardiac Surgery, Pitié-Salpêtrière - Charles Foix Hospital, AP-HP, Paris, France. Electronic address: pascal.leprince@aphp.fr.

Anatol Kontush (A)

National Institute for Health and Medical Research (INSERM), UMR ICAN 1166, Sorbonne University Paris 6, Pitié-Salpêtrière - Charles Foix Hospital, AP-HP, Paris, France. Electronic address: anatol.kontush@upmc.fr.

Jean-Christophe Charniot (JC)

Department of Cardiac Surgery, Pitié-Salpêtrière - Charles Foix Hospital, AP-HP, Paris, France. Electronic address: jean-christophe.charniot@aphp.fr.

Philippe Giral (P)

National Institute for Health and Medical Research (INSERM), UMR ICAN 1166, Sorbonne University Paris 6, Pitié-Salpêtrière - Charles Foix Hospital, AP-HP, Paris, France; Department of Endocrinology and Metabolism, Pitié-Salpêtrière - Charles Foix Hospital, AP-HP, Paris, France. Electronic address: philippe.giral@aphp.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH